Psoriasis News and Research

Latest Psoriasis News and Research

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

2 Jun 2014

WHO member states recognize psoriasis as chronic, non-communicable disease

At the 67th World Health Assembly, the WHO member states adopted a resolution on psoriasis, recognizing it as "a chronic, non-communicable, painful, disfiguring, and disabling disease for which there is no cure."

27 May 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

Study finds increased risk of hospitalization for heart failure in IBD patients

Heart failure hospitalisation more than doubles during inflammatory bowel disease (IBD) flares, according to a study of more than 5 million Danish people. The research was presented today at the Heart Failure Congress 2014, held 17-20 May, in Athens, Greece.

19 May 2014

Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014.

16 May 2014

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain.

From Quest Diagnostics 14 May 2014

Melbourne researchers find link between necroptosis and inflammatory disease

A team of Melbourne researchers has shown a recently discovered type of cell death called necroptosis could be the underlying cause of inflammatory disease.

13 May 2014

PhotoMedex revenues decrease 12% to $50.1 million in first quarter 2014

PhotoMedex, Inc. reports financial results for the three months ended March 31, 2014 and announces LCA-Vision stockholder approval of PhotoMedex's previously announced acquisition of all outstanding shares of LCA-Vision, a leading provider of laser vision correction services under the LasikPlus brand.

12 May 2014

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Antares Pharma, Inc. today reported operating and financial results for the first quarter ended March 31, 2014.

9 May 2014

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV.

8 May 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor.

6 May 2014

FABP5 protein enhances cognitive function

Case Western Reserve researchers have discovered that a protein previously implicated in disease plays such a positive role in learning and memory that it may someday contribute to cures of cognitive impairments.

5 May 2014

GPs need enhanced training to help manage patients with psoriasis, say experts

GPs need enhanced training to help them to manage patients with the complex, long term condition psoriasis which affects 1.8 million people in the UK, experts from The University of Manchester argue.

2 May 2014

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has submitted a study protocol to the U.S. Food and Drug Administration for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

29 Apr 2014

Emilia Group completes acquisition of Pharma Pac's strategic assets

Emilia Group is pleased to announce the recent acquisition of strategic assets of Pharma Pac LLC, an OTC private brand and contract manufacturer, located in DeKalb, MS. The new entity is named Emilia Resources LLC and will operate as a manufacturing company of pharmaceutical and cosmetic products that will combine with Emilia Personal Care's strength in sales, marketing, supply chain and customer service.

28 Apr 2014

NPF researchers to get access to Corrona’s psoriatic arthritis registry to improve patient outcomes

To improve treatment decisions and patient outcomes for psoriatic arthritis (PsA)—a chronic inflammatory arthritis that affects the joints and tendons—the National Psoriasis Foundation and Corrona, LLC are collaborating to give NPF-affiliated researchers access to Corrona’s psoriatic arthritis registry, which is the largest psoriatic arthritis registry in the world.

25 Apr 2014

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.

23 Apr 2014

AARDA launches autoimmune curriculum for teachers of grades three through eight

Furthering its mission of educating all Americans about autoimmunity and autoimmune disease (AD), the American Autoimmune Related Diseases Association, Inc. (AARDA) has launched the first-of-its kind autoimmune curriculum for teachers of grades three through eight.

22 Apr 2014

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).

21 Apr 2014

Psoriasis News and Research

Latest Psoriasis News and Research

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

WHO member states recognize psoriasis as chronic, non-communicable disease

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

Study finds increased risk of hospitalization for heart failure in IBD patients

Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Melbourne researchers find link between necroptosis and inflammatory disease

PhotoMedex revenues decrease 12% to $50.1 million in first quarter 2014

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

FABP5 protein enhances cognitive function

GPs need enhanced training to help manage patients with psoriasis, say experts

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Emilia Group completes acquisition of Pharma Pac's strategic assets

NPF researchers to get access to Corrona’s psoriatic arthritis registry to improve patient outcomes

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

AARDA launches autoimmune curriculum for teachers of grades three through eight

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in